4933428G09Rik Inhibitors
Chemical inhibitors of 4933428G09Rik can target various signaling pathways and cellular processes to modulate the activity of this protein. Staurosporine, a broad-spectrum protein kinase inhibitor, can impede the function of 4933428G09Rik by obstructing its phosphorylation or the phosphorylation of proteins associated with its regulation. Similarly, alsterpaullone, which targets cyclin-dependent kinases, can disrupt cell cycle-related signaling that may affect 4933428G09Rik activity. PD173074 and LY294002 are more pathway-specific inhibitors, targeting the FGFR tyrosine kinase and PI3K, respectively. If 4933428G09Rik functions downstream of FGFR signaling, PD173074 can inhibit this activity, while LY294002 can suppress AKT phosphorylation and subsequent PI3K signaling events that regulate 4933428G09Rik. Additionally, PD98059 and U0126, both targeting MEK within the MAPK/ERK pathway, can inhibit the function of 4933428G09Rik by preventing the activation of ERK.
Inhibitors like SB203580 and SP600125 can obstruct the p38 MAPK and JNK signaling cascades. If 4933428G09Rik is part of or is regulated by these pathways, the use of SB203580 can lead to a reduction in the activation of p38's downstream targets, while SP600125 can inhibit JNK activity. Rapamycin, an mTOR inhibitor, can also suppress the function of 4933428G09Rik if it is involved in the mTOR signaling pathway by halting mTOR's downstream effects. In terms of cytoskeletal dynamics, Y-27632, a ROCK kinase inhibitor, can affect 4933428G09Rik activity by disrupting ROCK-regulated pathways. Lastly, ZM-447439, which inhibits Aurora kinases, can interfere with cell cycle regulation or mitosis, processes in which 4933428G09Rik might play a role, by inhibiting Aurora kinase activity. Each of these inhibitors can contribute to the understanding of 4933428G09Rik's role in cellular functions by selectively modulating signaling pathways and protein interactions that are crucial for its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a wide range of protein kinases. If 4933428G09Rik is a kinase or is regulated by kinase activity, staurosporine could inhibit its function by preventing its phosphorylation or the phosphorylation of related proteins. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase. If 4933428G09Rik requires acidic vesicular organelles for its function, inhibition of this ATPase can raise the pH and thus inhibit 4933428G09Rik. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs). If 4933428G09Rik is regulated by the cell cycle or associated with CDKs, alsterpaullone can inhibit its function by disrupting cell cycle-dependent signaling pathways. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an inhibitor of the FGFR tyrosine kinase. If 4933428G09Rik is part of the FGFR signaling pathway, PD173074 can inhibit the pathway's activity, and therefore the function of 4933428G09Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. If 4933428G09Rik is downstream of PI3K signaling, inhibition of PI3K by LY294002 will reduce AKT phosphorylation and subsequent signaling that regulates 4933428G09Rik function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. If 4933428G09Rik is regulated by ERK signaling, inhibition by PD98059 can prevent activation of ERK and thus inhibit 4933428G09Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase. If 4933428G09Rik is part of the p38 MAPK signaling cascade, inhibition of p38 by SB203580 can result in decreased activation of downstream targets and inhibition of 4933428G09Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. If 4933428G09Rik is regulated by JNK signaling, inhibition by SP600125 can prevent JNK's activity and subsequent signaling that might regulate 4933428G09Rik function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth and proliferation. If 4933428G09Rik is involved in mTOR signaling, rapamycin can inhibit its function by blocking the activity of mTOR and its downstream effects. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of ROCK kinase. If 4933428G09Rik is involved in pathways regulated by ROCK, such as cytoskeleton organization, Y-27632 can inhibit its function by blocking ROCK activity. | ||||||